Helsinki, Finland – Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company, today announced that it has partnered with Pharmanovia, a fast-growing specialty pharma business with a portfolio of over 20 branded drugs in 140 markets.
The new strategic partnership aims to add value to branded prescription medicines. Pharmanovia will look to apply Nanoform’s proprietary nanoparticle technologies and formulation know-how to leading established pharmaceutical brands.
The partnership starts with an iconic branded medicine where both parties see value in enhancing bioavailability for patient benefit. The value of the stage-gated agreement is according to Nanoform’s business model for non-GMP and cGMP work.
“This partnership is a great example of where the power of small can add value for iconic medicines to make them even more effective. Pharmanovia’s business model enables brand loyalty to continue from one generation to the next,” said Christian Jones, Chief Commercial Officer of Nanoform.
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services. Nanoform’s unique technology provides novel opportunities in many value-enhancing drug delivery applications.